To the Editor:

Gritz et al[@bib1] make several significant points regarding wellness during the coronavirus disease 2019 pandemic in pediatrics in London, United Kingdom. We appreciate their contribution to recognizing the critical nature of wellness, and the important issues at hand. The pandemic has caused unprecedented transformations of health care facilities worldwide, including training programs.[@bib1] ^,^ [@bib2] A shift to telemedicine and virtual teaching has occurred as part of the initial phase of the pandemic response. However, as the gradual reopening of organizations, including health care facilities, transpires, we face new challenges of how to deliver the safest and most effective care. A number of considerations exist for resuming in-office practice, including physician and staff safety, logistics of the practice space, and resumption of procedures in the office.[@bib3] ^,^ [@bib4] Alongside of this, physicians in training and new fellowship graduates have their own additional stressors, including future employment and economic uncertainties. Before the pandemic, physician wellness was an escalating issue; unquestionably, in the aftermath of the first wave of the pandemic, there is a paramount need to continue to assess and address physician wellness needs.[@bib2] To accomplish this, we as a medical community need to collaborate, learn from the supports we are using during this crisis, and take deliberate action to create an enduring culture of wellness as we navigate both daily practice and potential future waves of the pandemic.
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